Skip to content
    Reviews

    Sentinel Lymph Node Mapping in Molecularly Classified Endometrial Cancer

    Tinelli et alJournal of Clinical Medicine

    Sentinel Lymph Node Mapping in Molecularly Classified Endometrial Cancer
    Sentinel lymph node (SLN) mapping represents an established approach for surgical nodal staging in presumed uterine-confined endometrial cancer, though its integration with molecular risk assessment presents unresolved clinical questions. In a narrative review evaluating mapping techniques and tumor biology across POLEmut, MMRd, NSMP, and p53abn tumors, cervical indocyanine green (ICG) injection paired with near-infrared imaging supported reproducible pelvic mapping, with comparative studies favoring ICG over blue dye.
    Prospective high-risk cohorts demonstrate high diagnostic accuracy when a complete mapping algorithm is applied; however, current evidence does not establish survival non-inferiority across every histologic or molecular subgroup. In the setting of an unmapped hemipelvis, technical reassessment is required, with ongoing surgical management dictated by baseline staging indications and operative feasibility. Furthermore, negative pelvic SLNs do not rule out all para-aortic metastases, indicating that additional para-aortic evaluation should address specific, defined treatment-planning questions.
    Pathologically, low-volume nodal disease remains bifurcated: micrometastases constitute formal nodal metastases, whereas isolated tumor cells are categorized as pN0(i+). While molecular profiling refines prognostic interpretation, molecularly annotated data have not validated subgroup-specific treatment algorithms for low-volume disease, highlighting the need for future trials to evaluate therapeutic alterations, morbidity, and oncologic endpoints rather than nodal detection alone.

    Key Takeaways

    • Comparative tracer studies favor cervical indocyanine green injection with near-infrared imaging over blue dye for reproducible pelvic sentinel lymph node mapping.
    • Prospective high-risk cohorts demonstrate high diagnostic accuracy when a complete surgical algorithm is applied, but survival non-inferiority across every histologic or molecular subgroup is not established.
    • Pathologic assessment classifies micrometastases as nodal metastases and isolated tumor cells as pN0(i+), though molecularly annotated cohorts have not validated subgroup-specific treatment rules for low-volume nodal disease.
    Read the original sourceJournal of Clinical Medicine